Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 603

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Open access
Pethe, Kevin, Bifani, Pablo, Jang, Jichan, Kang, Sunhee, Park, Seijin, Ahn, Sujin, Jiricek, Jan, Jung, Juyoung, Jeon, Hee Kyoung, Cechetto, Jonathan, Christophe, Thierry, Lee, Honggun, Kempf, Marie, Jackson, Mary, Lenaerts, Anne J, Pham, Ha, Jones, Victoria, Seo, Min Jung, Kim, Young Mi, Seo, Mooyoung, Seo, Jeong Jea, Park, Dongsik, Ko, Yoonae, Choi, Inhee, Kim, Ryangyeo, Kim, Se Yeon, Lim, SeungBin, Yim, Seung-Ae, Nam, Jiyoun, Kang, Hwankyu, Kwon, Haejin, Oh, Chun-Taek, Cho, Yoojin, Jang, Yunhee, Kim, Junghwan, Chua, Adeline, Tan, Bee Huat, Nanjundappa, Mahesh B, Rao, Srinivasa P S, Barnes, Whitney S, Wintjens, René, Walker, John R, Alonso, Sylvie, Lee, Saeyeon, Kim, Jungjun, Oh, Soohyun, Oh, Taegwon, Nehrbass, Ulf, Han, Sung-Jun, No, Zaesung, Lee, Jinhwa, Brodin, Priscille, Cho, Sang-Nae, Nam, Kiyean, Kim, Jaeseung·2013·Nature Medicine

Abstract

New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease, which remain a serious public health challenge worldwide. The most urgent clinical need is to discover potent agents capable of reducing the duration of MDR and XDR tuberculosis therapy with a success rate comparable to that of current therapies for drug-susceptible tuberculosis. The last decade has seen the discovery of new agent classes for the management of tuberculosis, several of which are currently in clinical trials. However, given the high attrition rate of drug candidates during clinical development and the emergence of drug resistance, the discovery of additional clinical candidates is clearly needed. Here, we report on a promising class of imidazopyridine amide (IPA) compounds that block Mycobacterium tuberculosis growth by targeting the respiratory cytochrome bc1 complex. The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound. In addition, Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Together, our data indicate that Q203 is a promising new clinical candidate for the treatment of tuberculosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.3262

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 603

Metadata

Authors
Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H. K., Cechetto, J., Christophe, T., Lee, H., Kempf, M., Jackson, M., Lenaerts, A. J., Pham, H., Jones, V., Seo, M. J., Kim, Y. M., Seo, M., Seo, J. J., Park, D., Ko, Y., Choi, I., Kim, R., Kim, S. Y., Lim, S., Yim, S.-A., Nam, J., Kang, H., Kwon, H., Oh, C.-T., Cho, Y., Jang, Y., Kim, J., Chua, A., Tan, B. H., Nanjundappa, M. B., Rao, S. P. S., Barnes, W. S., Wintjens, R., Walker, J. R., Alonso, S., Lee, S., Kim, J., Oh, S., Oh, T., Nehrbass, U., Han, S.-J., No, Z., Lee, J., Brodin, P., Cho, S.-N., Nam, K., & Kim, J.
Venue
Nature Medicine
Published
2013-08-04
Volume
19
Issue
9
Pages
1157-1160
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2092679747
Cited by
603
References
5
FWCI
26.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.